TABLE 3.
Combination | Reference(s) | No. of patients | CHR (%) | CCyR (%) | alloHSCT (%) | Median OS (mo) |
---|---|---|---|---|---|---|
Ponatinib + FLAG‐IDA | 10 | 17 (incl. 4 lBP) | 19 | 50 | 70.6 | 12 |
Dasatinib + FLAG‐IDA | 98 | 4 (incl 1 lBP) | 100 | 75 | 100 | N/A |
Imatinib + ‘7+3’ daunorubicin/cytarabine | 99 | 36 | 56 | 30.6 | 30.6 | 16 |
Imatinib + idarubicin/idarubicin + cytarabine | 100 | 19 | 47 | 15.8 | 26.3 | 5 |
Imatinib + mitoxantrone/etoposide | 101 | 16 | 81 | N/A | 37.5 | 6.4 |
Imatinib + decitabine | 53 | 10 | 20 | 10 | N/A | 3.5 |
Dasatinib + decitabine | 54 | 30 (incl AP n = 7 and Ph+AML n = 4) | 48 | 33.3 | 26.7 | 13.8 |
Dasatinib or nilotinib or ponatinib + azacytidine | 55 | 7 | 71 | 43 | N/A | 27.4 |
Imatinib + omacetaxine | 102 | 12 | 58 | 27.3 | 72.7 | N/A; 75% OS at 12 months |
Abbreviations: alloHSCT, allogeneic haemopoietic stem cell transplantation; AP, accelerated phase; CCyR, complete cytogenetic remission; CHR, complete haematologic remission; FLAG‐IDA, fludarabine, cytarabine, granulocyte‐colony stimulating factor, idarubicin; lBP, lymphoid blast phase; N/A, data not available; OS, overall survival; Ph+AML, Philadelphia chromosome‐positive acute myeloid leukaemia.